NasdaqGS - Delayed Quote USD
Kiniksa Pharmaceuticals International, plc (KNSA)
26.77
-0.17
(-0.63%)
At close: May 7 at 4:00:00 PM EDT
26.82
+0.05
+(0.19%)
Pre-Market: 8:17:57 AM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
481,166
423,239
270,259
220,180
38,544
Cost of Revenue
91,184
60,910
33,407
22,895
9,100
Gross Profit
389,982
362,329
236,852
197,285
29,444
Operating Expense
405,784
407,945
262,048
187,512
186,080
Operating Income
-15,802
-45,616
-25,196
9,773
-156,636
Net Non Operating Interest Income Expense
--
--
--
1,253
97
Other Income Expense
9,491
9,464
8,544
1,253
97
Pretax Income
-6,311
-36,152
-16,652
11,026
-156,539
Tax Provision
10,639
7,041
-30,736
-172,337
1,385
Net Income Common Stockholders
-16,950
-43,193
14,084
183,363
-157,924
Diluted NI Available to Com Stockholders
-16,950
-43,193
14,084
183,363
-157,924
Basic EPS
-0.23
-0.60
0.20
2.64
-2.30
Diluted EPS
-0.24
-0.60
0.20
2.60
-2.30
Basic Average Shares
71,927.68
71,424.16
70,058.95
69,382.28
68,576.81
Diluted Average Shares
72,802.31
71,424.16
71,922.92
70,421.32
68,576.81
Total Operating Income as Reported
-15,802
-45,616
-25,196
9,773
-156,636
Total Expenses
496,968
468,855
295,455
210,407
195,180
Net Income from Continuing & Discontinued Operation
-16,950
-43,193
14,084
183,363
-157,924
Normalized Income
-16,950
-43,193
14,084
183,363
-157,924
Interest Income
--
--
--
1,253
97
Net Interest Income
--
--
--
1,253
97
EBIT
-15,802
-45,616
-25,196
9,773
-156,636
EBITDA
-14,228
-43,921
-22,855
12,175
-154,281
Reconciled Cost of Revenue
91,184
60,910
33,407
22,895
9,100
Reconciled Depreciation
1,574
1,695
2,341
2,402
2,355
Net Income from Continuing Operation Net Minority Interest
-16,950
-43,193
14,084
183,363
-157,924
Normalized EBITDA
-14,228
-43,921
-22,855
12,175
-154,281
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 5/25/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CRDL Cardiol Therapeutics Inc.
1.0750
+1.42%
AMPH Amphastar Pharmaceuticals, Inc.
24.43
+2.35%
COLL Collegium Pharmaceutical, Inc.
27.05
+0.07%
NBIX Neurocrine Biosciences, Inc.
121.61
+2.26%
BCRX BioCryst Pharmaceuticals, Inc.
10.08
-1.85%
ALKS Alkermes plc
30.38
+0.07%
AVDL Avadel Pharmaceuticals plc
9.47
+9.61%
ZYBT Zhengye Biotechnology Holding Limited
11.52
-12.26%
ORGO Organogenesis Holdings Inc.
5.18
-0.38%
HLN Haleon plc
10.76
+0.84%